Program
MRNA-1982
A development code. Also written as “mRNA-1982”.
Its studies are mostly in Lyme Disease, led by Moderna.
Furthest: phase 2, since Jul 26, 20232 company-led studies, 1 open or runningNext primary completion: Nov 9, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 21 open or running | phase 2since Jul 26, 2023 | Jul 26, 2023 | Nov 9, 2028phase 2 · NCT07561294 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2023First study: phase 2 study in Lyme DiseaseFirst studyNCT05975099 · 807 enrolled · United States
- Apr 24, 2026Phase 2 study in Lyme DiseaseNCT07561294 · 366 enrolled · Canada
Ahead
- Nov 9, 2028Primary completion: phase 2 study in Lyme DiseaseNCT07561294
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07561294Lyme Disease · Canada | 2 | Active, not recruiting | Nov 9, 2028 | 366 |
| NCT05975099Lyme Disease · United States | 2 | Completed | May 30, 2025 | 807 |
How it is read
Names in the registry
- “mRNA-1982”, 2 entries
Codes read as this program: MRNA1982.
Conditions, from the studies’ own filings
- Lyme Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.